Get started
Madrigal Pharmaceuticals, Inc.Madrigal Pharmaceuticals, Inc.Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

MDGL trade ideas

Madrigal Pharmaceuticals (MDGL) AnalysisPioneering Treatments for NASH: Madrigal Pharmaceuticals NASDAQ:MDGL is leading the charge in developing treatments for non-alcoholic steatohepatitis (NASH). Its drug, Rezdiffra, is the only approved treatment for metabolic-associated steatohepatitis (MASH). With ongoing research to expand its indications, Madrigal is well-positioned in a market projected to be worth $12 billion to $35 billion annually. Market Potential and Analyst Outlook: Analysts forecast Rezdiffra’s peak sales could exceed $5 billion, with clinical trials for cirrhosis treatment potentially expanding its market by 2026-2027. Given its innovative treatment, strong market potential, and positive analyst outlook, Madrigal is a compelling investment opportunity. Investment Outlook: Bullish Outlook: We are bullish on MDGL above the $255.00-$257.00 range. Upside Potential: With an upside target set at $430.00-$440.00, investors should consider Madrigal's pioneering drug development and significant market potential as key drivers for future stock appreciation. 📊💊 Monitor Madrigal Pharmaceuticals for promising investment opportunities! #MDGL #BiopharmaGrowth 📈🔍
NASDAQ:MDGLLong
by Richtv_official
FDA Approves Madrigal's Treatment for NASH Liver DiseaseThe Food and Drug Administration (FDA) has granted approval to Madrigal Pharmaceuticals' ( NASDAQ:MDGL ) groundbreaking drug, Rezdiffra, as the first-ever treatment for nonalcoholic steatohepatitis (NASH) liver disease. This approval marks a significant breakthrough in the medical landscape, providing hope for millions worldwide battling this potentially deadly condition. NASH, characterized by excess fat buildup and inflammation in the liver, has long posed a formidable challenge for medical researchers and pharmaceutical companies alike. Madrigal's success in obtaining FDA approval for Rezdiffra represents a triumph in a disease area where several larger companies have previously faltered. The approval of Rezdiffra underscores its efficacy in treating patients with NASH who also have moderate-to-advanced liver scarring, a population previously underserved by available treatments. Notably, the drug must be used in conjunction with diet and exercise, offering a comprehensive approach to managing this complex condition. With an estimated 6 to 8 million individuals in the U.S. affected by NASH with moderate-to-advanced liver scarring, the approval of Rezdiffra brings newfound hope for those grappling with the debilitating effects of this disease. Madrigal's ( NASDAQ:MDGL ) commitment to accessibility is commendable, as the company has established an assistance program to ensure that individuals without insurance can access Rezdiffra. Rezdiffra's mechanism of action, which involves activating a thyroid hormone receptor in the liver to reduce fat accumulation, offers a promising avenue for addressing the underlying pathology of NASH. Results from late-stage studies have demonstrated the drug's ability to improve symptoms and liver scarring without exacerbating the condition, paving the way for its accelerated approval by the FDA. Despite the groundbreaking nature of Rezdiffra's approval, ongoing research and monitoring will be essential to further elucidate its clinical benefits and long-term outcomes. Madrigal's ( NASDAQ:MDGL ) commitment to conducting additional studies underscores its dedication to advancing the understanding and treatment of NASH. As Rezdiffra prepares for availability in April, the medical community eagerly anticipates its impact on patients' lives and the broader landscape of NASH treatment. With Rezdiffra's approval, Madrigal Pharmaceuticals has not only achieved a significant milestone but has also opened new possibilities for addressing the complexities of NASH and improving patient outcomes. In conclusion, the FDA's approval of Rezdiffra represents a triumph of innovation and perseverance in the fight against NASH liver disease. Madrigal Pharmaceuticals' ( NASDAQ:MDGL ) groundbreaking treatment offers hope for millions and marks a pivotal moment in the quest for effective therapies for this debilitating condition.
NASDAQ:MDGLLong
by DEXWireNews
MDGL: Daily VCPSetup: PowerPlay VCP: 6W 19/5 3T RS: 99 The posted chart contains a VCP (volatility contraction pattern). The first label "W" stands for weekly and shows the duration of the entire consolidation. In the middle label, the percentage of contractions is indicated (for example, "15/4"), with 15 representing the -15% depth of the base and 4 representing -4% of the last contraction. The last part "T" represents the number of contractions. The light blue lines in the chart correspond to the contractions. A more detailed description can be found in Mark Minervini's books. RS stands for relative strength and measures the strength of the stock compared to the overall market. The value range is 1-99 with 99 being the highest value. The rank was generated by fyntrade.
NASDAQ:MDGLLong
by fyntrade
MDGL, Aroon Indicator entered an Uptrend on October 21, 2020Over the last three days, Tickeron A.I.dvisor has detected that MDGL's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring call options in the next month. Tickeron A.I.dvisor backtested this indicator and found 188 similar cases, 168 of which were successful. Based on this data, the odds of success are 89%. Current price $132.12 is above $121.80 the highest resistance line found by Tickeron A.I. Throughout the month of 09/21/20 - 10/21/20, the price experienced a +5% Uptrend, while the week of 10/14/20 - 10/21/20 shows a -0.09% Downtrend. Bullish Trend Analysis The Momentum Indicator moved above the 0 level on October 07, 2020. You may want to consider a long position or call options on MDGL as a result. Tickeron A.I. detected that in 75 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%. MDGL moved above its 50-day Moving Average on September 14, 2020 date and that indicates a change from a downward trend to an upward trend. The 10-day Moving Average for MDGL crossed bullishly above the 50-day moving average on September 17, 2020. This indicates that the trend has shifted higher and could be considered a buy signal. Tickeron A.I. detected that in 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%. Following a +3.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 179 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 76%. The Aroon Indicator entered an Uptrend today. In 168 of 188 cases where MDGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
NASDAQ:MDGLLong
by AlTorress
MDGL, Aroon Indicator entered an Uptrend on Oct 14, 2020.Over the last three days, Tickeron A.I.dvisor has detected that MDGL's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring call options in the next month. Tickeron A.I.dvisor backtested this indicator and found 188 similar cases, 168 of which were successful. Based on this data, the odds of success are 89%. Current price $124.22 is above $121.80 the highest resistance line found by Tickeron A.I. Throughout the month of 09/14/20 - 10/14/20, the price experienced a +19% Uptrend. During the week of 10/07/20 - 10/14/20, the stock enjoyed a +1% Uptrend growth. Bullish Trend Analysis The Momentum Indicator moved above the 0 level on October 07, 2020. You may want to consider a long position or call options on MDGL as a result. Tickeron A.I. detected that in 64 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%. The Moving Average Convergence Divergence (MACD) for MDGL just turned positive on October 06, 2020. Looking at past instances where MDGL's MACD turned positive, the stock continued to rise, Tickeron A.I. shows that in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%. MDGL moved above its 50-day Moving Average on September 14, 2020 date and that indicates a change from a downward trend to an upward trend. The 10-day Moving Average for MDGL crossed bullishly above the 50-day moving average on September 17, 2020. This indicates that the trend has shifted higher and could be considered a buy signal. Tickeron A.I. detected that in 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%. Following a +3.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 177 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
NASDAQ:MDGLLong
by AlTorress
$MDGL can rise in the next daysContextual immersion trading strategy idea. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $118,32; stop-loss — $114,98. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:MDGLLong
by KozakHlib
2